Drug Report History
Below you will find the report version history. When a report is updated, a new version of the report is created. The report history allows you to see the changes between versions. You can select two versions of the report to compare. The fields that were changed between versions will be highlighted in yellow.
The translation of reports creates two separate versions which is why some reports may not seem to have any differences. In this case, only the language field below will be highlighted in yellow.
Version v21-EN | Version v10-EN | |
---|---|---|
Language | English | English |
Date Updated | 2022-12-20 | 2021-07-02 |
Drug Identification Number | 00585092 | 00585092 |
Brand name | DEPO-PROVERA STERILE AQUEOUS SUSPENSION 150 MG/ML | DEPO-PROVERA STERILE AQUEOUS SUSPENSION 150 MG/ML |
Common or Proper name | DEPO-PROVERA | DEPO-PROVERA |
Company Name | PFIZER CANADA ULC | PFIZER CANADA ULC |
Ingredients | MEDROXYPROGESTERONE ACETATE | MEDROXYPROGESTERONE ACETATE |
Strength(s) | 150MG | 150MG |
Dosage form(s) | SUSPENSION | SUSPENSION |
Route of administration | INTRAMUSCULAR INTRAMUSCULAR | INTRAMUSCULAR INTRAMUSCULAR |
Packaging size | 5 x 1ML | 5 x 1ML |
ATC code | G03AC | G03AC |
ATC description | HORMONAL CONTRACEPTIVES FOR SYSTEMIC USE | HORMONAL CONTRACEPTIVES FOR SYSTEMIC USE |
Reason for shortage | Disruption of the manufacture of the drug. | Disruption of the manufacture of the drug. |
Anticipated start date | 2021-07-01 | 2021-07-01 |
Actual start date | 2021-07-06 | |
Estimated end date | 2023-06-01 | 2022-06-01 |
Actual end date | 2022-08-05 | |
Shortage status | Resolved | Actual shortage |
Tier 3 Status | No | No |
Company comments | Product discontinued, see posting 178960. Other presentation available, pre-filled syringes (DIN 02523493) | Available inventory is currently on preventative allocation. Pfizer worked in collaboration with Health Canada and has received their authorization to import a batch of foreign-labelled supply of DEPO-PROVERA pre-filled syringes from the United States. Pfizer is committed to prioritize access to DEPO-PROVERA and is working diligently to have this alternate supply available in time to bridge the gap and mitigate any supply challenge with the product in 2021. |
Health Canada comments |